1. Home
  2. USIO vs PASG Comparison

USIO vs PASG Comparison

Compare USIO & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Usio Inc.

USIO

Usio Inc.

HOLD

Current Price

$1.50

Market Cap

32.3M

Sector

Finance

ML Signal

HOLD

PASG

Passage Bio Inc.

HOLD

Current Price

$5.13

Market Cap

26.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USIO
PASG
Founded
1998
2017
Country
United States
United States
Employees
N/A
27
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.3M
26.0M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
USIO
PASG
Price
$1.50
$5.13
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$4.00
$14.00
AVG Volume (30 Days)
55.5K
137.8K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$28,200,535.00
N/A
Revenue This Year
$12.15
N/A
Revenue Next Year
$8.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.69
N/A
52 Week Low
$1.03
$0.28
52 Week High
$2.02
$20.00

Technical Indicators

Market Signals
Indicator
USIO
PASG
Relative Strength Index (RSI) 69.20 41.63
Support Level $1.36 $3.94
Resistance Level $1.58 $7.76
Average True Range (ATR) 0.07 0.46
MACD 0.03 0.13
Stochastic Oscillator 73.48 63.79

Price Performance

Historical Comparison
USIO
PASG

About USIO Usio Inc.

Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.

About PASG Passage Bio Inc.

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

Share on Social Networks: